Cstone Pharmaceutical (Shanghai) Co Ltd

To evaluate the safety and tolerability of CS1002 in subjects with advanced/metastatic solid tumors; to determine the maximum tolerated dose (MTD, if any); to characterize the pharmacokinetic (PK) properties of CS1002; to evaluate the preliminary antitumor activity of CS1002; and to evaluate the immunogenicity of CS1002.

To compare the efficacy and safety of CS1001 combined with fluorouracil and cisplatin (FP) versus placebo combined with FP as first-line treatment for patients with unresectable locally advanced, recurrent or metastatic esophageal squamous cell carcinoma; pharmacokinetic (PK) characteristics and immunogenicity

The aim is to evaluate the safety and efficacy of CS1003 combined with lenvatinib versus placebo combined with lenvatinib as first-line treatment for patients with advanced HCC.